AGIOS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
AGIO$31.76+1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands, except share and per share data) December 31: | 2023 | 2022 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $88,205 | $139,259 |
| Marketable securities | 688,723 | 643,860 |
| Accounts receivable, net | 2,810 | 2,206 |
| Inventory | 19,076 | 8,492 |
| Prepaid expenses and other current assets | 35,021 | 38,955 |
| Total current assets | 833,835 | 832,772 |
| Marketable securities | 29,435 | 313,874 |
| Operating lease assets | 54,409 | 65,129 |
| Property and equipment, net | 15,382 | 22,987 |
| Other non-current assets | 4,057 | 3,956 |
| Total assets | $937,118 | $1,238,718 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,780 | $18,616 |
| Accrued expenses | 43,167 | 30,350 |
| Operating lease liabilities | 15,008 | 13,663 |
| Total current liabilities | 67,955 | 62,629 |
| Operating lease liabilities, net of current portion | 56,988 | 71,996 |
| Other non-current liabilities | 1,156 | 3,279 |
| Total liabilities | 126,099 | 137,904 |
| Commitments and contingent liabilities (Note 16) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 2022 | 72 | 71 |
| Additional paid-in capital | 2,436,523 | 2,386,325 |
| Accumulated other comprehensive loss | (441) | (12,535) |
| Accumulated deficit | (822,649) | (470,561) |
| Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022) | (802,486) | (802,486) |
| Total stockholders’ equity | 811,019 | 1,100,814 |
| Total liabilities and stockholders’ equity | $937,118 | $1,238,718 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.